or Try an Advanced Search...

    Technical Analysis for ESPR - Esperion Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 2.52 2.02% 0.05
    ESPR closed up 2.02 percent on Friday, November 22, 2024, on 79 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ESPR trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Crossed Above 20 DMA Bullish 4.56%
    Crossed Above 200 DMA Bullish 4.56%
    MACD Bullish Signal Line Cross Bullish 4.56%
    Up 3 Days in a Row Strength 4.56%
    20 DMA Resistance Bearish 17.21%
    NR7 Range Contraction 17.21%
    Older End-of-Day Signals for ESPR ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 13 hours ago
    Rose Above Previous Day's High about 17 hours ago
    Up 2% about 17 hours ago
    Up 1% about 17 hours ago
    Upper Bollinger Band Resistance about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ESPR Chart by TradingView
    Basic chart:

    Profile

    Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Low Density Lipoprotein Atherosclerosis Gabaa Receptor Positive Allosteric Modulators Niacin

    Is ESPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 21 Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
    Nov 18 Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
    Nov 13 Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
    Nov 8 Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
    Nov 7 Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
    Nov 7 Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
    Nov 7 Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
    Nov 7 Esperion Therapeutics: Q3 Earnings Snapshot
    Nov 7 Esperion Therapeutics gives mixed Q3 results
    Nov 7 Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
    See more ESPR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.4
    52 Week Low 1.1601
    Average Volume 4,015,636
    200-Day Moving Average 2.22
    50-Day Moving Average 2.03
    20-Day Moving Average 2.22
    10-Day Moving Average 2.34
    Average True Range 0.16
    RSI (14) 64.03
    ADX 27.96
    +DI 34.48
    -DI 17.78
    Chandelier Exit (Long, 3 ATRs) 2.11
    Chandelier Exit (Short, 3 ATRs) 2.36
    Upper Bollinger Bands 2.56
    Lower Bollinger Band 1.89
    Percent B (%b) 0.94
    BandWidth 30.25
    MACD Line 0.11
    MACD Signal Line 0.08
    MACD Histogram 0.0223
    Fundamentals Value
    Market Cap 450.89 Million
    Num Shares 179 Million
    EPS -2.27
    Price-to-Earnings (P/E) Ratio -1.11
    Price-to-Sales 4.49
    Price-to-Book 74.89
    PEG Ratio -4.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.66
    Resistance 3 (R3) 2.65 2.59 2.63
    Resistance 2 (R2) 2.59 2.56 2.60 2.62
    Resistance 1 (R1) 2.56 2.54 2.58 2.57 2.62
    Pivot Point 2.50 2.50 2.51 2.51 2.50
    Support 1 (S1) 2.47 2.47 2.49 2.48 2.42
    Support 2 (S2) 2.41 2.45 2.42 2.42
    Support 3 (S3) 2.38 2.41 2.41
    Support 4 (S4) 2.39